Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Dr. Jeff Cleland_2023
VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots:Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DMEJeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DMEThe interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…
January 3, 2023

Read more

Viewpoints_Patrick Mooney
VIEWPOINTS

Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic Eye Conditions

Shots:Patrick spoke about the 3-month data from the First-in-Human glaucoma treatment trial of Spyglass’ innovative  drug delivery platform that helps in lowering intraocular pressure in patients with glaucoma or ocular hypertensionPatrick also talked about the study design and key findings from the First-in-Human glaucoma treatment trialThe interview gives an understanding of Spyglass’…
November 29, 2022

Read more